Search results - ORA - Oxford University Research Archive

1 - 15 of 15

1

Journal article

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Krueger, JG, Eyerich, K, Kuchroo, VK, et al.
2024-04-15

2

Journal article

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Coates, LC, Landewé, R, McInnes, IB, et al.
2024-02-22

3

Journal article

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study

Ritchlin, CT, Coates, LC, McInnes, IB, et al.
2023-05-30

4

Journal article

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria

Ritchlin, CT, Coates, LC, Mease, PJ, et al.
2023-01-10

5

Journal article

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Merola, JF, Landewé, R, McInnes, IB, et al.
2022-12-06

6

Journal article

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

McInnes, IB, Asahina, A, Coates, LC, et al.
2023-01-06

7

Journal article

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study

Orbai, A-M, Coates, LC, Deodhar, A, et al.
2022-06-30

8

Journal article

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Coates, L, Ritchlin, CT, Gossec, L, et al.
2022-06-29

9

Journal article

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis

Pournara, E, Kormaksson, M, Nash, P, et al.
2021-11-18

10

Conference item

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free

Coates, LC, Ritchlin, CT, Gossec, L, et al.
2021-05-19

11

Conference item

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial

Orbai, AM, Coates, LC, Deodhar, A, et al.
2021-05-19

12

Journal article

GRAPPA 2019 project report

Goel, N, Coates, LC, De Marco, G, et al.
2020-06-01

13

Journal article

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

Singh, JA, Guyatt, G, Ogdie, A, et al.
2018-11-30

14

Journal article

GRAPPA 2018 project report

Goel, N, Fitzgerald, O, Gladman, DD, et al.
2019-06-01

15

Conference item

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity

Mease, PJ, Gladman, DD, Collier, D, et al.
2019-05-27

TO TOP